Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2012-12-20

Original market date: See footnote 1

2012-12-20

Product name:

STRIBILD

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02397137

Product Monograph/Veterinary Labelling:

Date: 2021-07-26 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

GILEAD SCIENCES CANADA INC
400 6925 Century Avenue, Suite 400
Mississauga
Ontario
Canada L5N 7K2

Class:

Human

Dosage form(s):

Tablet

Route(s) of administration:

Oral

Number of active ingredient(s):

4

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

92:92.00  ,  08:18.08.12  ,  08:18.08.20 

Anatomical Therapeutic Chemical (ATC): See footnote 4

J05AR09 EMTRICITABINE, TENOFOVIR DISOPROXIL, ELVITEGRAVIR AND COBICISTAT

Active ingredient group (AIG) number:See footnote5

0453433001

List of active ingredient(s)
Active ingredient(s) Strength
COBICISTAT 150 MG
ELVITEGRAVIR 150 MG
EMTRICITABINE 200 MG
TENOFOVIR DISOPROXIL FUMARATE 300 MG

Risk Management Plans See footnote 7

A Risk Management Plan (RMP) for this product was submitted.

Additional Risk Minimization Measures
Healthcare Professional Education
Version 4.0.2
Date modified: